Skip to main content
main-content

01.12.2012 | Research article | Ausgabe 1/2012 Open Access

BMC Health Services Research 1/2012

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults

Zeitschrift:
BMC Health Services Research > Ausgabe 1/2012
Autoren:
Daniel Polsky, Machaon Bonafede, Jose A Suaya
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1472-6963-12-379) contains supplementary material, which is available to authorized users.

Competing interests

Dr. Polsky has received consulting fees from GlaxoSmithKline. Dr. Suaya is employed by the GlaxoSmithKline group of companies. At the time of this study, Suaya worked at GlaxoSmithKline Vaccines. Dr. Bonafede is a employee of Thompson Reuters.

Authors’ contributions

All three authors have contributed to the conception, design, analysis, and interpretation of the data; the drafting and revising of the manuscript for important intellectual content; and have given final approval.

Abstract

Background

Adults with certain comorbid conditions have a higher risk of pneumonia than the overall population. If treatment of pneumonia is more costly in certain predictable situations, this would affect the value proposition of populations for pneumonia prevention. We estimate the economic impact of community-acquired pneumonia (CAP) for adults with asthma, diabetes, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) in a large U.S. commercially-insured working age population.

Methods

Data sources consisted of 2003 through 2007 Thomson Reuters MarketScan Commercial Claims and Encounters and Thomson Reuters Health Productivity and Management (HPM) databases. Pneumonia episodes and selected comorbidities were identified by ICD-9-CM diagnosis codes. By propensity score matching, controls were identified for pneumonia patients. Excess direct medical costs and excess productivity cost were estimated by generalized linear models (GLM).

Results

We identified 402,831 patients with CAP between 2003 through 2007, with 25,560, 32,677, 16,343, and 5,062 episodes occurring in patients with asthma, diabetes, COPD and CHF, respectively. Mean excess costs (and standard error, SE) of CAP were $14,429 (SE=44) overall. Mean excess costs by comorbidity subgroup were lowest for asthma ($13,307 (SE=123)), followed by diabetes ($21,395 (SE=171)) and COPD ($23,493 (SE=197)); mean excess costs were highest for patients with CHF ($34,436 (SE=549)). On average, indirect costs comprised 21% of total excess costs, ranging from 8% for CHF patients to 27% for COPD patients.

Conclusions

Compared to patients without asthma, diabetes, COPD, or CHF, the excess cost of CAP is nearly twice as high for patients with diabetes and COPD and nearly three times as high for patients with CHF. Indirect costs made up a significant but varying portion of excess CAP costs. Returns on prevention of pneumonia would therefore be higher in adults with these comorbidities.
Zusatzmaterial
Authors’ original file for figure 1
12913_2012_2475_MOESM1_ESM.tiff
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

BMC Health Services Research 1/2012 Zur Ausgabe